EX-10.2 3 dex102.htm AMENDED AND RESTATED DEVELOPMENT AND LICENSING AGREEMENT CERTAIN INFORMATION IN THIS EXHIBIT IS SUBJECT TO A REQUEST FOR CONFIDENTIAL TREATMENT. IN ACCORDANCE WITH RULE 24b-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED,...Development and Licensing Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionThis Amended and Restated Development and Licensing Agreement (“Agreement”) is made and entered into as of the 25th day of February, 2004 (the “Effective Date”), between Tanox, Inc. (formerly known as Tanox Biosystems, Inc.), originally a Texas corporation and reincorporated as a Delaware corporation (“Tanox”), and Novartis Pharma AG, a company organized and existing under the laws of Switzerland (as successor-in-interest of Ciba-Geigy Limited) (“Novartis”). (Each of Novartis and Tanox is referred to herein individually as a “Party” and all are referred to collectively herein as the “Parties.”)
AMENDED AND RESTATED DEVELOPMENT AND LICENSING AGREEMENTDevelopment and Licensing Agreement • May 10th, 2004 • Tanox Inc • Pharmaceutical preparations • New York
Contract Type FiledMay 10th, 2004 Company Industry JurisdictionThis Amended and Restated Development and Licensing Agreement (“Agreement”) is made and entered into as of the 25th day of February, 2004 (the “Effective Date”), between Tanox, Inc. (formerly known as Tanox Biosystems, Inc.), originally a Texas corporation and reincorporated as a Delaware corporation (“Tanox”), and Novartis Pharma AG, a company organized and existing under the laws of Switzerland (as successor-in-interest of Ciba-Geigy Limited) (“Novartis”). (Each of Novartis and Tanox is referred to herein individually as a “Party” and all are referred to collectively herein as the “Parties.”)